Email this article Radiotheranostics of neuroendocrine neoplasms: quo vadis
- Authors: Rumyantsev P.O.1
-
Affiliations:
- International Medical Center "SOGAZ"
- Issue: Vol 49, No 4 (2021)
- Pages: 297-303
- Section: POINT OF VIEW
- URL: https://almclinmed.ru/jour/article/view/1583
- DOI: https://doi.org/10.18786/2072-0505-2021-49-048
- ID: 1583
Cite item
Full Text
Abstract
Neuroendocrine neoplasms are grouped based on their neuroendocrine origin and represented by a heterogeneous tumor cluster with various malignancy potentials and types of biological behavior. These tumors can localize anywhere, but most commonly within the gastrointestinal tract. The ability of tumor cells to express specific receptors and particulars of their metabolism make it possible to successfully use molecular visualization (single-photon emission computed tomography / positron emission tomography) and radiotargeted therapy for diagnosis and treatment of patients with neuroendocrine tumors. In clinical practice, somatostatin receptor (receptors type 2) radiotheranostics has been used most widely. Improvement of diagnostic and therapeutic characteristics of new radioligands, discovery of new receptor and metabolic targets, widening of the medical isotope spectrum and development of new theranostic pairs open wide horizons for radiotheranostics as an integral field in modern biomedicine. The paper summarizes the worldwide experience, highlights the state-of-the-art and future development of radiotheranostics of neuroendocrine tumors.
About the authors
P. O. Rumyantsev
International Medical Center "SOGAZ"
Author for correspondence.
Email: pavelrum@gmail.com
ORCID iD: 0000-0002-7721-634X
Pavel O. Rumyantsev - MD, PhD, Deputy Chief Physician.
17-5 prospekt 60-letiya Oktyabrya, Moscow, 117312; 8 Malaya Konyushennaya ul., Saint Petersburg, 191186.
Russian FederationReferences
- Румянцев ПО, Коренев СВ. История появления терапии радиоактивным йодом. Клиническая и экспериментальная тиреоидология. 2015;11(4):51-55. doi: 10.14341/ket2015451_55.
- Баранова ОД, Румянцев ПО, Слащук КЮ, Петров ЛО. Радионуклидная диагностика и терапия у пациентов с нейроэндокринными опухолями. Эндокринная хирургия. 2018;11(4):178-190. doi: 10.14341/serg9572.
- Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, Kostakoglu L, Serafini AN, Pampaloni MH, Jensen J, Armor T, Lin T, White T, Stambler N, Apfel S, DiPippo VA, Mahmood S, Wong V, Jimenez C. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60(5):623-630. doi: 10.2967/jnumed.118.217463.
- Румянцев ПО, Языкова ДР, Слащук КЮ, Дегтярев МВ, Ясюченя ВС, Серженко СС, Шеремета МС, Дедов ИИ. Персонализированная диагностика хромаффинных опухолей (феохромоцитома, параганглиома) в онкоэндокринологии. Эндокринная хирургия. 2018;12(1):19-39. doi: 10.14341/serg9731.
- Refardt J, Hofland J, Kwadwo A, Nicolas GP, Rottenburger C, Fani M, Wild D, Christ E. Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. Rev Endocr Metab Disord. 2021;22(3):581-594. doi: 10.1007/s11154-020-09552-x.
- Briganti V, Cuccurullo V, Berti V, Di Stasio GD, Linguanti F, Mungai F, Mansi L. 99mTc-EDDA/HYN-IC-TOC is a new opportunity in neuroendocrine tumors of the lung (and in other malignant and benign pulmonary diseases). Curr Radiopharm. 2020;13(3):166-176. doi: 10.2174/1874471013666191230143610.
- Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Oberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125-135. doi: 10.1056/NEJMoa1607427.
- Weich A, Werner RA, Buck AK, Hartrampf PE, Serfling SE, Scheurlen M, Wester HJ, Meining A, Kircher S, Higuchi T, Pomper MG, Rowe SP, Lapa C, Kircher M. CXCR4-directed PET/CT in patients with newly diagnosed neuroendocrine carcinomas. Diagnostics (Basel). 2021;11(4):605. doi: 10.3390/diagnostics11040605.
- White JM, Escorcia FE, Viola NT. Perspectives on metals-based radioimmunotherapy (RIT): moving forward. Theranostics. 2021;11(13): 6293-6314. doi: 10.7150/thno.57177.
- Koustoulidou S, Hoorens MWH, Dalm SU, Mahajan S, Debets R, Seimbille Y, de Jong M. Cancer-associated fibroblasts as players in cancer development and progression and their role in targeted radionuclide imaging and therapy. Cancers (Basel). 2021;13(5):1100. doi: 10.3390/ cancers13051100.
- Boschi A, Martini P, Janevik-Ivanovska E, Duatti A. The emerging role of copper-64 radiopharmaceuticals as cancer theranostics. Drug Discov Today. 2018;23(8):1489-1501. doi: 10.1016/j. drudis.2018.04.002.
- Singh A, van der Meulen NP, Muller C, Klette I, Kulkarni HR, Turler A, Schibli R, Baum RP. First-in-human PET/CT imaging of metastatic neuroendocrine neoplasms with cyclotron-produced 44Sc-DOTATOC: A proof-of-concept study. Cancer Biother Radiopharm. 2017;32(4):124-132. doi: 10.1089/cbr.2016.2173.
- Mansi R, Fani M. Radiolabeled peptides for cancer imaging and therapy: from bench-to-bed-side. Chimia (Aarau). 2021;75(6):500-504. doi: 10.2533/chimia.2021.500.
- Kunikowska J, Krolicki L. Targeted a-emitter therapy of neuroendocrine tumors. Semin Nucl Med. 2020;50(2):171-176. doi: 10.1053/j.sem-nuclmed.2019.11.003.
Supplementary files
